IJMS | Free Full-Text | The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance | HTML
Combining Celecoxib with Sorafenib Synergistically Inhibits Hepatocellular Carcinoma Cells In Vitro | Anticancer Research
Systemic Therapies in Hepatocellular Carcinoma
Sorafenib mechanism of action: tumor proliferation and angiogenesis.... | Download Scientific Diagram
Mechanism of Action | NEXAVAR® (sorafenib) Global HCP Website
Mechanisms of sorafenib resistance. Sorafenib as an anticancer drug is... | Download Scientific Diagram
Figure 1 from New knowledge of the mechanisms of sorafenib resistance in liver cancer | Semantic Scholar
Pexa-Vec/Nexavar Combination Fails Phase III Trial in Liver Cancer
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma - ScienceDirect
TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma - Lai - 2019 - Molecular Oncology - Wiley Online Library
Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy
Mechanism of Action | Multikinase Inhibitors
Sorafenib: 10 years after the first pivotal trial | Future Oncology
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects | Signal Transduction and Targeted Therapy
Sorafenib - Mechanism of Action in treating Advanced Hepatocellular Carcinoma
Potential mechanisms of action of Sorafenib in RCC. Note: Sorafenib can... | Download Scientific Diagram
View of SUSTAINED RELEASE TABLETS OF SORAFENIB-SILIBININ COMBINATIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | International Journal of Applied Pharmaceutics
Sorafenib (NEXAVAR)®
IJMS | Free Full-Text | Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment | HTML
Sorafenib (Nexavar) - Oncology Nurse Advisor
Medicina | Free Full-Text | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. - Abstract - Europe PMC
